These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17938193)

  • 21. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.
    Rodríguez JC; Cebrián L; López M; Ruiz M; Jiménez I; Royo G
    J Antimicrob Chemother; 2004 Mar; 53(3):441-4. PubMed ID: 14963069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin.
    Shi G; Chen X; Wang H; Wang S; Guo X; Zhang X
    J Antibiot (Tokyo); 2012 May; 65(5):229-36. PubMed ID: 22334239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen.
    Koh WJ; Hong G; Kim SY; Jeong BH; Park HY; Jeon K; Kwon OJ; Lee SH; Kim CK; Shin SJ
    Antimicrob Agents Chemother; 2013 May; 57(5):2281-5. PubMed ID: 23478956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
    Ji B; Lefrançois S; Robert J; Chauffour A; Truffot C; Jarlier V
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1921-6. PubMed ID: 16723546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis.
    Miyazaki E; Miyazaki M; Chen JM; Chaisson RE; Bishai WR
    Antimicrob Agents Chemother; 1999 Jan; 43(1):85-9. PubMed ID: 9869570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Susceptibility of Mycobacterium tuberculosis strains to gatifloxacin and moxifloxacin by different methods.
    Somasundaram S; Paramasivan NC
    Chemotherapy; 2006; 52(4):190-5. PubMed ID: 16714850
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Swaminath S; Paul A; Pradhan A; Sebastian J; Nair RR; Ajitkumar P
    Microbiology (Reading); 2020 Feb; 166(2):180-198. PubMed ID: 31746727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones.
    Blondeau JM; Blondeau LD; Hesje C; Borsos S
    J Chemother; 2006 Aug; 18(4):366-72. PubMed ID: 17024791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.
    Louie A; Heine HS; VanScoy B; Eichas A; Files K; Fikes S; Brown DL; Liu W; Kinzig-Schippers M; Sörgel F; Drusano GL
    Antimicrob Agents Chemother; 2011 Feb; 55(2):822-30. PubMed ID: 21115791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.
    Drusano GL; Sgambati N; Eichas A; Brown DL; Kulawy R; Louie A
    mBio; 2010 Aug; 1(3):. PubMed ID: 20802826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
    Hesje CK; Borsos SD; Blondeau JM
    J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
    Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
    PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis.
    Sulochana S; Mitchison DA; Kubendiren G; Venkatesan P; Paramasivan CN
    J Chemother; 2009 Apr; 21(2):127-34. PubMed ID: 19423464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimising moxifloxacin resistance with tuberculosis.
    Drlica K; Zhao X; Kreiswirth B
    Lancet Infect Dis; 2008 May; 8(5):273-5. PubMed ID: 18471768
    [No Abstract]   [Full Text] [Related]  

  • 35. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
    Sulochana S; Rahman F; Paramasivan CN
    J Chemother; 2005 Apr; 17(2):169-73. PubMed ID: 15920901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
    Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model.
    Kesteman AS; Ferran AA; Perrin-Guyomard A; Laurentie M; Sanders P; Toutain PL; Bousquet-Mélou A
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4740-8. PubMed ID: 19738020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains.
    Tortoli E; Dionisio D; Fabbri C
    J Chemother; 2004 Aug; 16(4):334-6. PubMed ID: 15332706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of mycobacterial resistance to quinolone class antimicrobials.
    Malik M; Chavda K; Zhao X; Shah N; Hussain S; Kurepina N; Kreiswirth BN; Kerns RJ; Drlica K
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3879-87. PubMed ID: 22564842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
    Nuermberger E; Tyagi S; Williams KN; Rosenthal I; Bishai WR; Grosset JH
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1452-6. PubMed ID: 16151038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.